Cell-Free In Vitro Protein Expression Platform : Two European Patents Granted To Proteus
NIMES, France--(BUSINESS WIRE)--May 3, 2004--Proteus today announced the issuance of European patents EP 1,137,804 and EP 1,137,801 covering specific embodiments and application of the Phenomics(TM) technology for diagnosis and for target labeling respectively.
"The technology provides the company with a proprietary and powerful system for detecting target substances in a variety of samples and for diagnosis on the basis of the detection of the function of a protein. The issuance of these European patents combined with the recent issuance of U.S. Patent No. 6,514,703 significantly strengthens our intellectual property portfolio and our worldwide market exclusivity position with respect to cell-free in vitro protein expression." said Daniel Dupret, Chairman and CEO of Proteus.
"The major technology breakthrough provided by Phenomics(TM) is the ability to express functional proteins in a cell-free in vitro environment under an automated and high throughput format. We routinely use this revolutionary approach to explore our huge reservoir of biodiversity and screen valuable new enzymes and other proteins generated by our proprietary L-Shuffling(TM) directed evolution technology. We intend to license it for application that are outside of our core business," Daniel Dupret added.
Proteus is a leading biotechnology company in the field of discovery and engineering of novel proteins for pharmaceutical, cosmetics, fine chemicals, agrochemical and other industrial applications. The company's activities are supported by specialist know-how and a portfolio of proprietary elements. This portfolio includes a unique proprietary microbial biodiversity with a vast collection of micro-organisms originating from extreme environments and proprietary technologies for functional high throughput gene expression (Phenomics(TM)), screening (CLIPS-O(TM)) and for directed evolution (L-Shuffling(TM)). Products discovered and developed by Proteus exhibit novel and/or improved activity, efficiency and stability, thus conferring competitive advantages in large global markets. To address such large markets, Proteus works in close partnership with major players of the industry.
------------------------------------------------------------------------
Contact:
Proteus
Jean-Marie Sonet, +33-466-70-6464
Fax: +33-466-70-6460
info@proteus.fr
www.proteus.fr |
